$7.8 Billion Molecular Diagnostics Market Positioned for Significant Growth
Complete the form below to unlock access to ALL audio articles.
G2 Intelligence announces the release of U.S. Molecular Diagnostic and Genomic Testing 2013-2015: Laboratory Industry Analysis, Trends, and Forecasts, a new resource for stakeholders in MDx testing. In conjunction with the release of the study, G2 currently gauges the MDx market at $7.8 billion in 2013.
“Like other health care sectors, molecular diagnostics is experiencing disruptive forces that are redefining the very core of care, delivery, and reimbursement models,” according to L. Eleanor Herriman, M.D. M.B.A., Managing Director of G2 Intelligence Advisory Services, and one of the report’s analysts. “These forces are largely driven by the reactions of health care payers and policy makers to the national health care cost crisis, and the shift to a value-based system. MDx is uniquely positioned to play a central role in value-based health care, but must first navigate some challenging regulatory and payer issues.”
U.S. Molecular Diagnostic and Genomic Testing clarifies the market with:
• Market sizing and growth forecasts through 2015 across seven MDx sectors:
o Hematology-Oncology (Hem-Onc)
o Pharmacogenomics (PGx)
o Women’s Health
o General Infectious
o Blood Screening
• Analysis of key market drivers and inhibitors
• Platform usage by test type including:
o Abbott, ABI, Access, Autogenomics, BD (Becton, Dickinson and Company), Bio Rad Biocare, Cepheid, Dako, Focus, GenMark, Gen-Probe, Leica, Luminex Qiagen, Roche, Ventana and more
• Menu availability and in-house vs. send out analysis, by test including:
o Adenovirus, ALK, BCL-2, BCR/ABL, BK Virus, Bordetella, BRAF, C-Diff, Chlamydia/Gonorrhea, C-KIT, CMV Cytomegalovirus, Cystic Fibrosis, EBV (Epstein-Barr), EGFR, Enterovirus, FLT3, Group A Strep, Group B Strep,HBV Viral Load, HCV Viral Load and Genotyping, HER-2, Herpes (HSV), HIV Viral Load and Genotyping, HPV, HPV Genotyping, HPV non-cervical, Influenza A/B, JAK-2, KI-67, KRAS, MRSA or SA, Norovirus, Respiratory Virus, Trich, Tuberculosis, VRE, VZV (Varicella Zoster)
• How and why Pharmacogenomics is poised to grow
• Next Generation Sequencing challenges and solutions
• And much more...
“Where there is volatility, there is opportunity,” says Jennifer Musumeci, MS, and Associate Director of G2’s Advisory Services. “While there is significant variability in growth rates within MDx sectors, the overall market will expand in 2013, despite the bumpy road in the short term. It’s essential for labs, IVD manufacturers, health care payers and providers to find out where they stand, and where these game-changing diagnostics are headed. This new report fills that void with a wealth of valuable data.”